Vasant Prakash Gandhi
Chief Executive Officer at Molecular Decisions Strategy LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Bradway | M | 61 | 18 years | |
| Robert Eckert | M | 69 | 21 years | |
| David Reese | M | 61 | 19 years | |
| Esteban Santos | M | 56 | 17 years | |
| Matthew Busch | M | 50 | 20 years | |
| Derek Miller | M | - | 21 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Douglas Williams | M | 66 |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 15 years |
| Lonnie Moulder | M | 66 |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 1 years |
| David W. Beier | M | 75 | 10 years | |
| Edward V. Fritzky | M | 73 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 11 years |
| Paul Eisenberg | M | - | 14 years | |
| Michael Kelly | M | 67 | 14 years | |
| Patrick Soon-Shiong | M | 71 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 3 years |
| Michael Severino | M | 58 | 10 years | |
| Craig Shepherd | M | - | 7 years | |
| Cynthia Flowers | F | 64 | 5 years | |
| Jean-Francois Gimonet | M | - |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 3 years |
| Gregory L. Tewalt | M | - | - | |
| Jin Long Chen | M | 61 | 4 years | |
| John Smither | M | 71 | 6 years | |
| Daniel J. Burge | M | 62 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 3 years |
| Willard Dere | M | 70 | 11 years | |
| William Ashton | M | 73 | 16 years | |
| Paul J. Carter | M | - |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 3 years |
| Sean B. W. Martin | M | 61 | - | |
| Wayne A. Davey | M | - |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 3 years |
| Cynthia Patton | F | 62 | 15 years | |
| Leonard Schaeffer | M | 78 | 9 years | |
| Patricia Cary Sueltz | F | 71 | 2 years | |
| Dominique Monnet | M | 65 | 11 years | |
| David J. Scott | M | 71 | - | |
| Nathan Hardy | M | 48 | 10 years | |
| Timothy Martin | M | 55 | 3 years | |
| Bruce Wendel | M | 70 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 4 years |
| Erin Lavelle | F | 46 | 15 years | |
| Susan Lundeen Smuck | F | 57 | 12 years | |
| Diana McKenzie | F | 59 | 12 years | |
| Anna Richo | F | 63 | - | |
| Frank Herringer | M | 81 | 15 years | |
| Peggy Phillips | F | 70 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 6 years |
| Deepak Nath | M | - | - | |
| Stuart Arbuckle | M | 58 | 8 years | |
| Joshua J. Ofman | M | 60 | 16 years | |
| Vimal Srivastava | M | 58 | 3 years | |
| Catherine Stehman-Breen | M | 61 | 12 years | |
| Diane Parks | F | 71 | 7 years | |
| Richard Davies | M | 62 | 9 years | |
| Andrew Knudten | M | - | 13 years | |
| Christophe Quéva | M | 57 | 5 years | |
| Majed Kheir | M | 46 | 6 years | |
| Timothy Powers | M | 58 | 5 years | |
| Jesse Seton McGreivy | M | 54 | 6 years | |
| Thomas-Christian Mix | M | 57 | 12 years | |
| Sesha Neervannan | M | 56 | 8 years | |
| David Weinreich | M | - | 7 years | |
| Marc D. Better | M | 68 | 5 years | |
| Brian Kotzin | M | 74 | 11 years | |
| Scott M. Wasserman | M | - | 14 years | |
| Edward A. Imbrogno | M | 60 | 7 years | |
| Yi Ning Zhao | M | 53 | 5 years | |
| James G. Stout | M | 58 | 4 years | |
| Michael Wittekind | M | 69 | 4 years | |
| Sunita Zalani | M | - | 8 years | |
| Eliot Charles | M | 62 | 3 years | |
| Eric Grinstead | M | 66 | 7 years | |
| Peter K. Watler | M | 62 | 12 years | |
| Helen Torley | M | 61 | 8 years | |
| David Hallal | M | 56 | 10 years | |
| Steven J. Ruhl | M | - | - | |
| Kevin B. Young | M | 66 | 3 years | |
| Wen-Tse Tseng | M | - | 5 years | |
| Terry Rosen | M | 65 | 9 years | |
| Stuart Tross | M | 57 | 10 years | |
| Oranee T. Daniels | M | - | - | |
| Michael Narachi | M | 64 | 20 years | |
| Stephen Blackwood | M | 61 | 7 years | |
| Maureen P. Brogan | F | 62 | 3 years | |
| Timothy McNamara | M | 67 | 3 years | |
| Doug Farrar | M | 59 | 7 years | |
| John F. Weidenbruch | M | 63 | 10 years | |
| Beth Seidenberg | M | 67 | 3 years | |
| Martha E. Vincent | M | - | 9 years | |
| T. Tyler Ellison | M | - | 1 years | |
| Dung Thai | M | - | - | |
| John G. Adair | M | - | 6 years | |
| Susan R. Lundeen-Smuck | F | 58 | 9 years | |
| David A. Boyden | M | 63 | 13 years | |
| Fanesca Young | M | - | 2 years | |
| Timothy Hoey | M | 65 | - | |
| Giuseppe Giorgini | M | - | - | |
| Joseph I. DePinto | M | 57 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 1 years |
| Warren Wayne Myers | M | 62 | 10 years | |
| Nick Abbott | M | - | 10 years | |
| Juan Jaen | M | 66 | 10 years | |
| Linda C. Heller | F | 60 | 4 years | |
| Frederick A. Fletcher | M | - | 10 years | |
| Carl LeBel | M | 65 | 10 years | |
| Bradley J. Maroni | M | 71 | 6 years | |
| Lisa A. Evrén | F | - | 5 years | |
| Qin Xia | F | 56 | 14 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Vasant Prakash Gandhi
- Personal Network
